Are Biotech’s Gearing up for a Run Higher?

Hey Gang, Happy Monday! I’d bet that after last week’s performance in the XBI and IBB, the biotech bulls are still smiling. And rightfully so, after all, the bulls had to withstand a downtrend lasting over a month before getting a sign of a reversal. When that sign arrived, [it arrived in a big way.]( On Friday, the XBI closed the day up 4.78% and the week up 5.19%. On December 6th, notice how the XBI put in a clear reversal candle. After that day, the XBI rallied towards the 20d MA. However, it could not firm up and hold above it. The XBI pulled back and made a new low by $0.04, and in doing so, put in a double bottom. Friday’s price action and close are significant because the XBI closed above the 20d MA on increased volume. Going forward, I would like to see the XBI hold above the 20d MA and make a push towards the 50d MA, which is currently at $121.33. This action is positive for the sector and specifically optimistic for small-cap biotechs. I am encouraged by the price action and opportunity I saw last week in small-cap biotechs, and I am confident about the potential for ample opportunities in 2022. But there’s still some year left, gang, and earlier this morning, I sent out my Weekly Watch List to my members, outlining my current holds and new additions to my list. One stock, which I have [written]( about before, is on my Watch List again. [Now I need you to CLICK HERE to see what I planning to do with it this time around.]( Jeff Williams RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Unsubscribe from all RagingBull emails]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com.